CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 01/15/21

Gainers: Ceragon Networks (CRNT) +67%.ObsEva (OBSV) +60%.Polar Power (POLA) +50%.Charah Solutions (CHRA) +46%.Avinger (AVGR) +45%.DBV Technologies (DBVT) +42%.Novan (NOVN) +42%.Senseonics (SENS) +42%.Atlantic Power (AT) +40%.Driven Brands (DRVN) +31%.Losers: Dogness (DOGZ)...

Cyclacel Pharmaceuticals (CYCC) outlines key business objectives for 2021. In 2021, Cyclacel will commence streamlined Phase 1/2 clinical studies, initially of oral fadraciclib and subsequently of oral CYC140, in a broad range of solid tumors and hematological malignancies. The aim of these s...

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Ac...

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Bio...

Ocugen (OCGN) +174%.Foresight Autonomous Holdings (FRSX) +84%.MicroVision (MVIS) +61%.Big Rock Partners Acquisition Corp. (BRPA) +56%.Aurora Mobile Limited (JG) +50%.Cyclacel Pharmaceuticals (CYCC) +50%.Aqua Metals (AQMS) +48%.LightPath Technologies (LPTH) +40%.Sportsman's Warehouse Holdings ...

Gainers: Ocugen (OCGN) +114%.Big Rock Partners Acquisition (BRPA) +110%.Aurora Mobile (JG) +50%.Aqua Metals (AQMS) +45%.NantHealth (NH) +39%.Sportsman's Warehouse Holdings (SPWH) +37%.Aemetis (AMTX) +30%.Foresight Autonomous Holdings (FRSX) +29%.QuantumScape (QS) +28%.Cyclacel Pharmaceut...

Cyclacel Pharmaceuticals (CYCC) has entered into securities purchase agreement with Acorn Bioventures, a biotech-focused fundamental investor. Under the agreement, Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 common shares and 237,745 Series B Preferred Sto...

- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY HEIGHTS, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals...

BERKELEY HEIGHTS, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Brian Schwartz,...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Eric Ando – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Opera...